{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T21:47:28Z","timestamp":1767304048723},"reference-count":74,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,1,18]],"date-time":"2012-01-18T00:00:00Z","timestamp":1326844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> In the last three decades there have been dramatic improvements in the availability and quality of treatment for people with inherited coagulation disorders. Indeed, the improvement of methods of purification and viral inactivation for plasma\u2010derived coagulation factor concentrates first and then the development of products utilizing recombinant DNA technology have greatly improved the life expectancy of hemophiliacs, which has progressively become similar to that of males in the general population. Nowadays, the most frequent complication of factor replacement therapy for hemophilia is the development of inhibitors. However, no studies so far have systematically analysed the type and incidence of other adverse reactions following the administration of coagulation factor concentrates. The aim of this systematic review was to screen the published literature data to evaluate the types and frequencies of non\u2010thrombotic\u2010, non\u2010inhibitor\u2010associated adverse reactions to coagulation factor concentrates in patients with hemophilia A, hemophilia B and von Willebrand\u2019s disease. On behalf the European Haemophilia Safety Surveillance System (EUHASS), a systematic review of the prospective studies published in the last 20\u2003years was performed using electronic databases and article references. Both severe and mild adverse events following infusion of coagulation factor concentrates are relatively rare in patients with inherited coagulation disorders; the most common events are of an allergic type. There are no differences in the rate of adverse events caused by plasma\u2010derived or recombinant products. On the whole, these data confirm the high degree of safety of the products currently used for replacement therapy.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2011.02745.x","type":"journal-article","created":{"date-parts":[[2012,1,18]],"date-time":"2012-01-18T11:08:39Z","timestamp":1326884919000},"source":"Crossref","is-referenced-by-count":17,"title":["Non\u2010thrombotic\u2010, non\u2010inhibitor\u2010associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand\u2019s disease: a systematic review of prospective studies"],"prefix":"10.1111","volume":"18","author":[{"given":"M.","family":"FRANCHINI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"MAKRIS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"SANTAGOSTINO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"COPPOLA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. M.","family":"MANNUCCI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,18]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106073442307"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61199-4"},{"key":"e_1_2_6_4_2","first-page":"117","article-title":"Evidence\u2010based recommendations on the treatment of von Willebrand disease in Italy","volume":"7","author":"Mannucci PM","year":"2009","journal-title":"Blood Transfus"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90166-3"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613227"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613225"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03899.x"},{"key":"e_1_2_6_9_2","unstructured":"European Commission.Directive 2001\/20\/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Available athttp:\/\/europa.eu.int\/eurlex\/pri\/en\/oj\/dat\/2001\/l_121\/l_12120010501en00340044.pdfAccessed October 10 2011."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199012273232604"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199302183280701"},{"key":"e_1_2_6_12_2","first-page":"2428","article-title":"A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients","volume":"83","author":"Bray GL","year":"1994","journal-title":"Blood"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1665410"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1656030"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00191.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613925"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00432.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00407.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(01)90108-8"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(01)90109-X"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2001.00511.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1351-8216.2001.00131.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00708.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02983823"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00730.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00932.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7933.2004.00646.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00947.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01131.x"},{"key":"e_1_2_6_30_2","first-page":"457","article-title":"Full\u2010length sucrose\u2010formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation","volume":"3","author":"Kreuz W","year":"2005","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01416.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01420.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01472.x"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01412.x"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03032.x"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH07-12-0724"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH07-06-0409"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH08-02-0117"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712590902729392"},{"key":"e_1_2_6_41_2","first-page":"32","article-title":"Clinical safety surveillance study of the safety and efficacy of long\u2010term home treatment with ReFacto utilizing a computer\u2010aided diary: a Nordic multicentre study","volume":"100","author":"Petrini P","year":"2009","journal-title":"Haemophilia"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02024.x"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02027.x"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02332.x"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03650.x"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02113.x"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02239.x"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02446.x"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02600.x"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02428.x"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2010.11.030"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02395.x"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02441.x"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1650217"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.13.3600"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00587.x"},{"key":"e_1_2_6_57_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613022"},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00721.x"},{"key":"e_1_2_6_59_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2283"},{"key":"e_1_2_6_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01160.x"},{"key":"e_1_2_6_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01458.x"},{"key":"e_1_2_6_62_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02162.x"},{"key":"e_1_2_6_63_2","article-title":"Clinical efficacy, safety and pharmacokinetic properties of the plasma\u2010derived factor IX concentrate Haemonine in previously treated patients with severe hemophilia B","author":"Serban M","year":"2011","journal-title":"Haemophilia"},{"key":"e_1_2_6_64_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02470.x"},{"key":"e_1_2_6_65_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.2.450"},{"key":"e_1_2_6_66_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-27822"},{"key":"e_1_2_6_67_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1351-8216.2003.00809.x"},{"key":"e_1_2_6_68_2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1160\/TH04-02-0107","article-title":"In vitro studies, pharmacokinetic studies and clincal use of a high purity double virus inactivated FVIII\/VWF concentrate (Immunate) in the treatment of von Willebrand disease","volume":"92","author":"Ver Elst KMM","year":"2004","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_69_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01570.x"},{"key":"e_1_2_6_70_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02588.x"},{"key":"e_1_2_6_71_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02562.x"},{"key":"e_1_2_6_72_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01901.x"},{"key":"e_1_2_6_73_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02206.x"},{"key":"e_1_2_6_74_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-10-0631"},{"key":"e_1_2_6_75_2","unstructured":"MakrisM FischerK;European Haemophilia Safety Surveillance System (EUHASS). Annual Report. 217 March 2011. ISBN 978\u20101\u2010908155\u201003\u20100."}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2011.02745.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2011.02745.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T17:32:45Z","timestamp":1698687165000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2011.02745.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,18]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1111\/j.1365-2516.2011.02745.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2011.02745.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,18]]}}}